EYPT
Eyepoint Pharmaceuticals Inc
3.30$
+0.6%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -100.0% | -164.7% | -266.8% | -212.9% | -370.8% | -309.4% | -217.2% | -1,173.6% | -6,144.3% | -10,491.5% | -11,573.1% | -12,297.4% | -9,584.0% | |
| 0.8% | 0.8% | 2.6% | 3.8% | 3.9% | 4.0% | 2.0% | 10.1% | 59.6% | 112.6% | 91.4% | 136.1% | 93.2% | |
| 23.9% | 25.6% | 108.7% | 91.7% | 70.8% | 68.2% | 32.0% | 128.9% | 665.4% | 1,088.5% | 1,672.1% | 2,050.9% | 1,262.6% | |
| -41.4% | -87.5% | -122.5% | 34.6% | -148.7% | -9.5% | -59.3% | -174.1% | -587.5% | -695.3% | -1,036.4% | 4,443.0% | 191.0% | |
| 11.3% | 6.3% | 10.2% | 9.5% | 15.0% | 3.3% | 1.1% | 22.9% | 82.6% | 159.0% | 143.2% | 236.7% | 142.7% | |
| -11.3% | -336.1% | 178.1% | -1,692.5% | 153.9% | -828.1% | 161.6% | 906.4% | 5,733.4% | -12,042.9% | 8,484.8% | 14,813.0% | 4,118.9% | |
| – | – | -37.3% | -0.8% | -0.7% | – | – | – | – | – | – | 673.8% | – | |
| – | – | – | – | -0.7% | -0.3% | -0.1% | -0.3% | -2.8% | -4.4% | -4.2% | -5.5% | -4.0% | |
| 68.2% | 1,557.5% | 1.0% | 3.5% | 113.0% | 1,309.0% | -3.9% | 4.5% | 766.4% | 26,928.5% | -375.6% | 3,943.2% | 6,874.8% | |
| -43.2% | 1,056.7% | -87.7% | -1,901.9% | -103.9% | 171.5% | -59.5% | -262.8% | 355.5% | 4,394.2% | -3,463.9% | 6,458.8% | 1,409.6% | |
| -111.3% | -171.0% | -277.0% | -222.4% | -385.8% | -312.7% | -218.4% | -1,196.5% | -6,226.9% | -10,650.5% | -11,716.4% | -12,534.1% | -9,726.7% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.